In Gleevec Feud, Novartis Targets Indian Patent Rules
In its ongoing battle to patent its cancer treatment Gleevec in India, Novartis AG has lashed out not only at the rejection of its patent application earlier this year, but at...To view the full article, register now.
Already a subscriber? Click here to view full article